Human Milk Nutrients and Infants' Health Outcomes in South China

NCT ID: NCT05432180

Last Updated: 2025-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-06

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the associations between human milk nutrients and infants' health outcomes in China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human milk components are beneficial to the growth and development of infants, such as phospholipids, gangliosides, sialic acids, choline, oligosaccharide and so on. However, studies on the associations between human milk components and infants' outcomes are limited. Therefore, this study is designed to investigate the relationship between Chinese human milk components and the growth and development of infants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 4-5 years
* healthy children
* breastfeeding between 0 to 400 days of age
* human milk components in human milk being determined
* sign informed consent

Exclusion Criteria

* children with severe chronic diseases, such as tumor, severe digestive diseases, kidney diseases
* gestational diabetes, hypertension and other metabolic diseases
* children with mental system diseases
* children with congenital and genetic diseases
* children with infectious diseases, eg, upper respiratory tract infection or diarrhea
* antibiotic or other drugs influencing intestinal flora being taken within 45 days
* Withdraw withdraw informed consent serious violation of the scheme no longer meet the research criteria because of health factors or accidents
Minimum Eligible Age

4 Years

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Huilian Zhu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Huilian Zhu

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Huilian Zhu, Professor

Role: STUDY_CHAIR

Sun Yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Yang MT, Lan QY, Pan C, Huang SY, Huang ZH, Li MC, Li Z, Li F, Li X, Zou JP, Chen HQ, Qiu YZ, Song S, Mao YY, Zhu HL. Long-term cognitive benefits of human milk phospholipids in breastfed children at preschool age: results from MUAI study. Eur J Nutr. 2025 Sep 23;64(7):283. doi: 10.1007/s00394-025-03801-y.

Reference Type DERIVED
PMID: 40986082 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MUAI-2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.